drugset / Trial / NCT00641615
Peptide Vaccine and S-1/CPT-11 Therapy for Patients With Unresectable Advanced Colorectal Cancer
Phase 1
Completed
18 enrolled
Kazuhiko Yoshimatsu
Human Genome Center, Institute of Medical Science, University of Tokyo · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and immune response of different doses of RNF43-721 emulsified with Montanide ISA 51 in combination with S-1/CPT-11 chemotherapy.
Timeline
- Start
- 2007-05
- Primary completion
- 2011-07
- Completion
- 2011-07
Publications
- Background Uchida N, Tsunoda T, Wada S, Furukawa Y, Nakamura Y, Tahara H. Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res. 2004 Dec 15;10(24):8577-86. doi: 10.1158/1078-0432.CCR-04-0104.
- Background Yoshimatsu K, Yokomizo H, Fujimoto T, Umehara A, Otani T, Matsumoto A, Osawa G, Ogawa K. Pilot study of simplified low-dose S-1 plus CPT-11 as first-line chemotherapy for patients with advanced colorectal cancer. Anticancer Res. 2007 May-Jun;27(3B):1657-61.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RNF43-721 | Unknown | 0.5 mg | — |
| Subject | RNF43-721 | Unknown | 1 mg | — |
| Subject | RNF43-721 | Unknown | 3 mg | — |